Today Lumen announced a new collaboration with Novo Nordisk to explore new treatments for cardiometabolic diseases. We couldn’t be more thrilled.
Cardiometabolic disease — a cluster of related conditions that includes obesity, diabetes, and cardiovascular disease — afflicts hundreds of millions of people worldwide, and the associated health and economic burdens continue to grow.
